Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2022.09.08

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Commences recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments

Sai Life Sciences, today announced plans to grow the scientific team at its site in Manchester, UK by 20% and commenced the process of recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments. View open positions.

Making the announcement, Dr Dean Edney, Global Head of Process R&D at Sai Life Sciences said, “In a little over two years since we began in Manchester, our team has established a formidable reputation for itself as a high-quality scientific unit that can solve complex chemistry challenges. Our growing list of global innovator clients is a strong validation of our success. The present recruitment drive is aimed at increasing our scientific capacity to better serve the growing demand.”

In July 2020, Sai Life Sciences opened a new Centre of Excellence in Process Chemistry R&D in Alderley Park, Manchester to help accelerate the NCE development programmes of its global innovator customers. This Centre has since grown to become a reliable partner to many innovator companies across the world, providing high quality chemistry, non-GMP material delivery, and successful technology transfer to its sites in India for scale-up.

Now, with a growing interest from its customers for clinical API supplies from Manchester, work is underway to set-up a GMP Kilo Lab at the Manchester site. Scheduled to be commissioned in Q4-2022, the new facility will be capable of delivering GMP drug substance and intermediates, with the GMP equipment engineered to provide containment down to 1µg/m3.

As part of the SaiNxt transformation initiative, the company has executed investments of US$110M in expanding into new geographies, augmenting its capacity and operations, while raising the bar for quality, compliance and performance.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more